JP2015526458A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015526458A5 JP2015526458A5 JP2015527922A JP2015527922A JP2015526458A5 JP 2015526458 A5 JP2015526458 A5 JP 2015526458A5 JP 2015527922 A JP2015527922 A JP 2015527922A JP 2015527922 A JP2015527922 A JP 2015527922A JP 2015526458 A5 JP2015526458 A5 JP 2015526458A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- nep inhibitor
- delay
- prevention
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 21
- 239000011780 sodium chloride Substances 0.000 claims description 21
- 206010007554 Cardiac failure Diseases 0.000 claims description 17
- 206010019280 Heart failure Diseases 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 230000001746 atrial Effects 0.000 claims description 15
- 206010003658 Atrial fibrillation Diseases 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butanoic acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 8
- 230000014759 maintenance of location Effects 0.000 claims description 8
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims description 7
- SJSNUMAYCRRIOM-QFIPXVFZSA-N Valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 238000007634 remodeling Methods 0.000 claims description 7
- 229960004699 valsartan Drugs 0.000 claims description 7
- 210000002381 Plasma Anatomy 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 claims description 4
- 238000011105 stabilization Methods 0.000 claims description 2
- 230000002459 sustained Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 5
- HCRBXQFHJMCTLF-UHFFFAOYSA-N Ethyl 2-methylbutyrate Chemical compound CCOC(=O)C(C)CC HCRBXQFHJMCTLF-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 description 77
- 230000002401 inhibitory effect Effects 0.000 description 77
- 239000000651 prodrug Substances 0.000 description 40
- 229940002612 prodrugs Drugs 0.000 description 40
- 102000018984 Angiotensin Receptors Human genes 0.000 description 7
- 108010012129 Angiotensin Receptors Proteins 0.000 description 7
- 239000003087 receptor blocking agent Substances 0.000 description 7
- 229940079593 drugs Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 2
- 230000000087 stabilizing Effects 0.000 description 2
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- AEBRINKRALSWNY-SCSAIBSYSA-N (2R)-4-amino-2-methylbutanoic acid Chemical compound OC(=O)[C@H](C)CCN AEBRINKRALSWNY-SCSAIBSYSA-N 0.000 description 1
- 208000005846 Cardiomyopathy Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000006887 Mitral Valve Stenosis Diseases 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 201000008031 cardiomyopathy Diseases 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018228452A JP7407508B2 (ja) | 2012-08-24 | 2018-12-05 | 心房拡大又はリモデリングを特徴とする疾患を治療するためのｎｅｐ阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261692911P | 2012-08-24 | 2012-08-24 | |
| US61/692,911 | 2012-08-24 | ||
| PCT/EP2013/067472 WO2014029848A1 (en) | 2012-08-24 | 2013-08-22 | Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018228452A Division JP7407508B2 (ja) | 2012-08-24 | 2018-12-05 | 心房拡大又はリモデリングを特徴とする疾患を治療するためのｎｅｐ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015526458A JP2015526458A (ja) | 2015-09-10 |
| JP2015526458A5 true JP2015526458A5 (pt-PT) | 2016-11-24 |
| JP6482462B2 JP6482462B2 (ja) | 2019-03-13 |
Family
ID=49000959
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015527922A Active JP6482462B2 (ja) | 2012-08-24 | 2013-08-22 | 心房拡大又はリモデリングを特徴とする疾患を治療するためのｎｅｐ阻害剤 |
| JP2018228452A Active JP7407508B2 (ja) | 2012-08-24 | 2018-12-05 | 心房拡大又はリモデリングを特徴とする疾患を治療するためのｎｅｐ阻害剤 |
| JP2021155220A Pending JP2022020624A (ja) | 2012-08-24 | 2021-09-24 | 心房拡大又はリモデリングを特徴とする疾患を治療するためのｎｅｐ阻害剤 |
| JP2023124147A Withdrawn JP2023159114A (ja) | 2012-08-24 | 2023-07-31 | 心房拡大又はリモデリングを特徴とする疾患を治療するためのｎｅｐ阻害剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018228452A Active JP7407508B2 (ja) | 2012-08-24 | 2018-12-05 | 心房拡大又はリモデリングを特徴とする疾患を治療するためのｎｅｐ阻害剤 |
| JP2021155220A Pending JP2022020624A (ja) | 2012-08-24 | 2021-09-24 | 心房拡大又はリモデリングを特徴とする疾患を治療するためのｎｅｐ阻害剤 |
| JP2023124147A Withdrawn JP2023159114A (ja) | 2012-08-24 | 2023-07-31 | 心房拡大又はリモデリングを特徴とする疾患を治療するためのｎｅｐ阻害剤 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US9517226B2 (pt-PT) |
| EP (2) | EP3943084A1 (pt-PT) |
| JP (4) | JP6482462B2 (pt-PT) |
| KR (2) | KR102159601B1 (pt-PT) |
| CN (2) | CN104602711A (pt-PT) |
| AU (1) | AU2013304949C1 (pt-PT) |
| BR (1) | BR112015003067A2 (pt-PT) |
| CA (1) | CA2882771C (pt-PT) |
| CL (1) | CL2015000426A1 (pt-PT) |
| DK (1) | DK2887961T3 (pt-PT) |
| ES (1) | ES2879550T3 (pt-PT) |
| HK (1) | HK1205930A1 (pt-PT) |
| HU (1) | HUE054885T2 (pt-PT) |
| IL (1) | IL237114B (pt-PT) |
| MA (1) | MA37850A1 (pt-PT) |
| MX (1) | MX2015002432A (pt-PT) |
| NZ (1) | NZ704604A (pt-PT) |
| PH (1) | PH12015500375A1 (pt-PT) |
| PL (1) | PL2887961T3 (pt-PT) |
| PT (1) | PT2887961T (pt-PT) |
| RU (1) | RU2667643C2 (pt-PT) |
| SG (1) | SG11201500256UA (pt-PT) |
| SI (1) | SI2887961T1 (pt-PT) |
| TN (1) | TN2015000028A1 (pt-PT) |
| TW (1) | TWI634887B (pt-PT) |
| WO (1) | WO2014029848A1 (pt-PT) |
| ZA (1) | ZA201500262B (pt-PT) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| CN102838599A (zh) | 2006-05-04 | 2012-12-26 | 贝林格尔.英格海姆国际有限公司 | 多晶型 |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| SI2887961T1 (sl) | 2012-08-24 | 2021-08-31 | Novartis Ag | Zaviralci NEP za zdravljenje bolezni, značilnih po atrialni širitvi ali preoblikovanju |
| WO2015028941A1 (en) | 2013-08-26 | 2015-03-05 | Novartis Ag | New use |
| ES2950384T3 (es) * | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
| WO2015154673A1 (en) * | 2014-04-10 | 2015-10-15 | Zhaoyin Wang | Novel prodrugs and combinations for treatment of hypertension and cardiovascular diseases |
| HUE062195T2 (hu) | 2015-05-11 | 2023-10-28 | Novartis Ag | Szakubitril - valzartán adagolási rend szívelégtelenség kezelésére |
| JP2018516267A (ja) | 2015-05-29 | 2018-06-21 | ノバルティス アーゲー | 代謝性疾患を治療するためのサクビトリルおよびバルサルタン |
| CN106309388A (zh) * | 2015-06-30 | 2017-01-11 | 深圳信立泰药业股份有限公司 | 一种用于心衰治疗的药物组合物及其制备方法 |
| WO2017006254A1 (en) | 2015-07-08 | 2017-01-12 | Novartis Ag | Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist |
| CN105997993B (zh) * | 2015-07-11 | 2018-03-30 | 麦丽芳 | 一种用于心血管疾病治疗的固体口服型制剂及其制备方法 |
| CN105997994A (zh) * | 2015-07-11 | 2016-10-12 | 凌莉 | 一种固体口服型制剂及其制备方法 |
| US10596151B2 (en) | 2015-08-28 | 2020-03-24 | Novartis Ag | Methods and pharmaceutical compositions for reducing arterial stiffness with a combination of a therapeutic agent blocking the angiotensin receptor and a therapeutic agent inhibiting the NEP enzyme |
| JP6810152B2 (ja) | 2016-02-03 | 2021-01-06 | ノバルティス アーゲー | サクビトリルおよびバルサルタンの組合せの新規使用 |
| US11382866B2 (en) | 2017-07-06 | 2022-07-12 | Mankind Pharma Ltd. | Fixed dose pharmaceutical composition of valsartan and sacubitril |
| UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
| EP3840746A1 (en) | 2018-08-23 | 2021-06-30 | Novartis AG | New pharmaceutical use for the treatment of heart failure |
| WO2020039394A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | New drug combinations |
| MX2021010783A (es) | 2019-03-08 | 2021-09-30 | Boehringer Ingelheim Int | Formulaciones de anticuerpo anti-il-36r. |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3004206A1 (de) | 1980-02-06 | 1981-08-13 | Hoechst Ag, 6000 Frankfurt | Verfahren zur herstellung von 1-alkyl-1-phenylhydrazinen |
| DE3005674A1 (de) | 1980-02-15 | 1981-08-20 | Ruhr-Zink GmbH, 4354 Datteln | Verwendung einer blei-legierung fuer anoden bei der elektrolytischen gewinnung von zink |
| DE3010374A1 (de) | 1980-03-18 | 1981-10-08 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von copolymerisaten von styrol und/oder dessen derivaten |
| US4610816A (en) | 1980-12-18 | 1986-09-09 | Schering Corporation | Substituted dipeptides as inhibitors of enkephalinases |
| US4383527A (en) | 1981-02-20 | 1983-05-17 | Howmedica, Inc. | Device for guiding the insertion of surgical wires into bone tissue |
| ATE17267T1 (de) | 1981-04-24 | 1986-01-15 | Jean Martin | Vorgefertigte einheit zur herstellung eines baugeruestes. |
| ZA84670B (en) | 1983-01-31 | 1985-09-25 | Merck & Co Inc | Thiorphan analogs as enkephalinase and angiotensin converting enzyme inhibitors |
| US4722810A (en) | 1984-08-16 | 1988-02-02 | E. R. Squibb & Sons, Inc. | Enkephalinase inhibitors |
| US4929641B1 (en) | 1988-05-11 | 1994-08-30 | Schering Corp | Mercapto-acylamino acid antihypertensives |
| US4749688A (en) | 1986-06-20 | 1988-06-07 | Schering Corporation | Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension |
| US4740499A (en) | 1986-07-28 | 1988-04-26 | Monsanto Company | Method of enhancing the bioactivity of atrial peptides |
| GB8811873D0 (en) | 1988-05-19 | 1988-06-22 | Pfizer Ltd | Therapeutic agents |
| GB8812597D0 (en) | 1988-05-27 | 1988-06-29 | Pfizer Ltd | Therapeutic agents |
| GB2218983A (en) | 1988-05-27 | 1989-11-29 | Pfizer Ltd | Spiro-substituted glutaramides as diuretics |
| EP0361365A1 (en) | 1988-09-30 | 1990-04-04 | E.R. SQUIBB & SONS, INC. | Aminobenzoic and aminocyclohexane-carboylic acid compounds, compositions, and their method of use |
| GB8903740D0 (en) | 1989-02-18 | 1989-04-05 | Pfizer Ltd | Therapeutic agents |
| DE122007000050I1 (de) | 1990-02-19 | 2007-11-08 | Novartis Ag | Acylverbindungen |
| US5223516A (en) | 1990-03-22 | 1993-06-29 | E. R. Squibb & Sons, Inc. | 3,3,3-trifluoro-2-mercaptomethyl-N-tetrazolyl substituted propanamides and method of using same |
| GB9103454D0 (en) | 1991-02-19 | 1991-04-03 | Pfizer Ltd | Therapeutic agents |
| US5294632A (en) | 1991-05-01 | 1994-03-15 | Ciba-Geigy Corporation | Phosphono/biaryl substituted dipetide derivatives |
| US5273990A (en) | 1992-09-03 | 1993-12-28 | Ciba-Geigy Corporation | Phosphono substituted tetrazole derivatives |
| US5250522A (en) | 1992-10-09 | 1993-10-05 | Ciba-Geigy Corporation | Phosphono/biaryl substituted amino acid derivatives |
| GB9123353D0 (en) | 1991-11-04 | 1991-12-18 | Fujisawa Pharmaceutical Co | New mercapto-amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same |
| WO1993010773A1 (en) | 1991-12-06 | 1993-06-10 | Schering-Plough S.P.A. | Use of neutral endopeptidase inhibitors in the treatment of left ventricular hypertrophy |
| US5217996A (en) | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
| DE4233296C1 (de) | 1992-10-02 | 1994-03-31 | Heitland Und Petre Int Gmbh | Behälter für Kosmetikprodukte |
| WO1994015908A1 (en) | 1993-01-14 | 1994-07-21 | Yoshitomi Pharmaceutical Industries, Ltd. | Propionamide derivative and medicinal use thereof |
| JPH06234754A (ja) | 1993-02-10 | 1994-08-23 | Dai Ichi Seiyaku Co Ltd | 複素環式カルボン酸誘導体 |
| IT1266571B1 (it) | 1993-07-30 | 1997-01-09 | Zambon Spa | Derivati della beta-mercapto-propanammide utili nel trattamento delle malattie cardiovascolari |
| JP3576193B2 (ja) | 1993-12-03 | 2004-10-13 | 第一製薬株式会社 | ビフェニルメチル置換バレリルアミド誘導体 |
| US6201002B1 (en) | 1997-01-10 | 2001-03-13 | Merck & Co., Inc. | Method for reducing mortality with an angiotensin II antagonist |
| DE60315795T2 (de) | 2002-01-17 | 2008-06-05 | Novartis Ag | Pharmazeutische zusammensetzung enthaltend valsartan und nep-inhibitoren |
| RU2245162C2 (ru) * | 2003-01-04 | 2005-01-27 | Козлов Владимир Александрович | Способ терапии инфаркта миокарда |
| MXPA05012299A (es) | 2003-05-16 | 2006-01-30 | Novartis Ag | Composicion farmaceutica que comprende valsartan. |
| MY146830A (en) * | 2005-02-11 | 2012-09-28 | Novartis Ag | Combination of organic compounds |
| AR057882A1 (es) * | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| PT2295035T (pt) | 2007-11-06 | 2016-08-22 | Novartis Ag | Composições farmacêuticas de dupla acção com base em superestruturas de antagonista/bloqueador de receptores de angiotensina (arb) com inibidor da endopeptidase neutra (nep) |
| KR101864865B1 (ko) * | 2010-08-24 | 2018-06-05 | 노파르티스 아게 | 항응고제 요법을 받고 있는 포유동물에서의 고혈압의 치료 및／또는 심부전의 예방 또는 치료 |
| SI2887961T1 (sl) | 2012-08-24 | 2021-08-31 | Novartis Ag | Zaviralci NEP za zdravljenje bolezni, značilnih po atrialni širitvi ali preoblikovanju |
-
2013
- 2013-08-22 SI SI201331902T patent/SI2887961T1/sl unknown
- 2013-08-22 DK DK13750725.7T patent/DK2887961T3/da active
- 2013-08-22 NZ NZ704604A patent/NZ704604A/en unknown
- 2013-08-22 CN CN201380044470.1A patent/CN104602711A/zh active Pending
- 2013-08-22 KR KR1020157004112A patent/KR102159601B1/ko active IP Right Review Request
- 2013-08-22 EP EP21168346.1A patent/EP3943084A1/en not_active Withdrawn
- 2013-08-22 KR KR1020207026971A patent/KR20200111822A/ko not_active Application Discontinuation
- 2013-08-22 BR BR112015003067A patent/BR112015003067A2/pt not_active IP Right Cessation
- 2013-08-22 MA MA37850A patent/MA37850A1/fr unknown
- 2013-08-22 MX MX2015002432A patent/MX2015002432A/es unknown
- 2013-08-22 HU HUE13750725A patent/HUE054885T2/hu unknown
- 2013-08-22 ES ES13750725T patent/ES2879550T3/es active Active
- 2013-08-22 CA CA2882771A patent/CA2882771C/en active Active
- 2013-08-22 PT PT137507257T patent/PT2887961T/pt unknown
- 2013-08-22 RU RU2015110240A patent/RU2667643C2/ru active
- 2013-08-22 AU AU2013304949A patent/AU2013304949C1/en active Active
- 2013-08-22 EP EP13750725.7A patent/EP2887961B1/en not_active Revoked
- 2013-08-22 WO PCT/EP2013/067472 patent/WO2014029848A1/en active Application Filing
- 2013-08-22 CN CN201810388983.9A patent/CN108685889A/zh active Pending
- 2013-08-22 JP JP2015527922A patent/JP6482462B2/ja active Active
- 2013-08-22 PL PL13750725T patent/PL2887961T3/pl unknown
- 2013-08-22 SG SG11201500256UA patent/SG11201500256UA/en unknown
- 2013-08-22 US US14/422,855 patent/US9517226B2/en active Active
- 2013-08-23 TW TW102130334A patent/TWI634887B/zh active
-
2015
- 2015-01-14 ZA ZA2015/00262A patent/ZA201500262B/en unknown
- 2015-01-19 TN TNP2015000028A patent/TN2015000028A1/fr unknown
- 2015-02-05 IL IL237114A patent/IL237114B/en active IP Right Grant
- 2015-02-20 PH PH12015500375A patent/PH12015500375A1/en unknown
- 2015-02-23 CL CL2015000426A patent/CL2015000426A1/es unknown
- 2015-07-02 HK HK15106283.6A patent/HK1205930A1/xx unknown
-
2016
- 2016-11-08 US US15/345,941 patent/US9937143B2/en active Active
-
2018
- 2018-03-06 US US15/912,701 patent/US11135192B2/en active Active
- 2018-12-05 JP JP2018228452A patent/JP7407508B2/ja active Active
-
2021
- 2021-09-24 JP JP2021155220A patent/JP2022020624A/ja active Pending
-
2023
- 2023-07-31 JP JP2023124147A patent/JP2023159114A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015526458A5 (pt-PT) | ||
| JP2022020624A (ja) | 心房拡大又はリモデリングを特徴とする疾患を治療するためのｎｅｐ阻害剤 | |
| JP6309454B2 (ja) | 癌の併用処置 | |
| JP2020529996A5 (pt-PT) | ||
| JP2014515373A5 (pt-PT) | ||
| EP3310168A1 (en) | Methods and compositions for treating herpesvirus induced conditions | |
| JP2010518122A5 (pt-PT) | ||
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| RU2012117563A (ru) | Режим дозирования модулятора рецептора s1p | |
| RU2010132581A (ru) | Способы терапии заболеваний легких | |
| JP2010540519A5 (pt-PT) | ||
| JP2017536380A (ja) | １５−ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法 | |
| JP2015522077A5 (pt-PT) | ||
| JP2019507786A5 (pt-PT) | ||
| WO2017148129A1 (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| JP2007169283A (ja) | 洞房結節Ｉｆ電流阻害剤およびアンギオテンシン変換酵素阻害剤の新規な組み合わせならびにそれを含む医薬組成物 | |
| RU2012107483A (ru) | Отамиксабан для лечения инфаркта миокарда без подъема сегмента st у пациентов пожилого возраста и пациентов с нарушенной функцией почек | |
| CN111132677A (zh) | 西尼莫德的给药方案 | |
| JP6328856B2 (ja) | 収縮力低下随伴性排尿筋過活動改善剤 | |
| RU2017142589A (ru) | Композиции и способы лечения или предупреждения легочной гипертензии | |
| JPWO2019246225A5 (pt-PT) | ||
| JP6227535B2 (ja) | 脂質異常症の予防又は治療薬 | |
| JP2011157395A5 (pt-PT) | ||
| JP2019001830A (ja) | 医薬 | |
| WO2019004465A1 (ja) | ペマフィブラートを含有する医薬 |